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Binge-eating disorder (BED) is characterized by recurring episodes of excessive consumption of palatable food and an increased sensitivity
to food cues. Patients with BED display an addiction-like symptomatology and the dopamine system might be a potential treatment target.
The clinically safe monoamine stabilizer (− )-OSU6162 (OSU6162) restores dopaminergic dysfunction in long-term alcohol-drinking rats
and shows promise as a novel treatment for alcohol use disorder. Here, the effects of OSU6162 on consummatory (binge-like eating) and
appetitive (cue-controlled seeking) behavior motivated by chocolate-flavored sucrose pellets were evaluated in non-food-restricted male
Lister Hooded rats. OSU6162 significantly reduced binge-like intake of chocolate-flavored sucrose pellets without affecting prior chow
intake. Furthermore, OSU6162 significantly reduced the cue-controlled seeking of chocolate-flavored sucrose pellets under a second-
order schedule of reinforcement before, but not after, the delivery and ingestion of reward, indicating a selective effect on incentive
motivational processes. In contrast, the dopamine D2/D3 receptor antagonist raclopride reduced the seeking of chocolate-flavored
sucrose pellets both pre- and post reward ingestion and also reduced responding under simpler schedules of seeking behavior. The D1/5
receptor antagonist SCH23390 had no effect on instrumental behavior under any reinforcement schedule tested. Finally, local
administration of OSU6162 into the nucleus accumbens core, but not dorsolateral striatum, selectively reduced cue-controlled sucrose
seeking. In conclusion, the present results show that OSU6162 reduces binge-like eating behavior and attenuates the impact of cues on
seeking of palatable food. This indicates that OSU6162 might serve as a novel BED medication.
Neuropsychopharmacology (2018) 43, 617–626; doi:10.1038/npp.2017.215; published online 25 October 2017
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INTRODUCTION
Binge-eating disorder (BED) is characterized by persistent
uncontrollable episodes of eating large amounts of palatable
food, and an increased responsivity to food-associated cues
(Schienle et al, 2009) inducing food cravings and overeating
(Curtis and Davis, 2014; Sobik et al, 2005). These behaviors
resemble symptoms of substance use disorders, including
loss of control over drug intake, drug cue sensitivity, and
craving (Cassin and von Ranson, 2007). The mesocortico-
limbic dopamine system may be implicated in the over-
lapping neural mechanisms between the two disorders, as
well as the reinforcing effects of both palatable foods and
drugs of abuse (Gonzales et al, 2004; Wise, 2006). In fact,
intake of both palatable food and drugs of abuse (Ericson
et al, 1998; Ito et al, 2000; Rada et al, 2005) and cues
associated with these reinforcers (Di Ciano et al, 1998; du
Hoffmann and Nicola, 2014) release dopamine in the nucleus
accumbens (NAc) in rodents. Similarly, in both BED (Wang
et al, 2011) and substance use disorders (Volkow et al, 2006),
dopamine is released in the striatum following the presenta-
tion of food- and drug-associated cues, respectively. More-
over, like chronic drug intake, chronic binge-like intake of
palatable food induces addictive-like behaviors and dopami-
nergic changes in the striatum (Avena, 2010; Naef et al,
2015), including decreased NAc dopamine D2 receptor levels
in rodents (Avena, 2007; Bello and Hajnal, 2010; Colantuoni
et al, 2001). In addition, genetic studies have associated
binge-eating pathology in humans with polymorphisms of
the dopamine transporter and D2 receptor (for review see
Bello and Hajnal, 2010). Finally, the monoamine-releasing
compound lisdexamfetamine is the only FDA-approved BED
medication (Davis and Attia, 2017). However, because of the
medication’s side effects and abuse potential, improved
treatment options are needed.
The monoamine stabilizer (− )-OSU6162 (OSU6162)
(Sonesson et al, 1994) is a clinically safe compound
(Johansson et al, 2012; Khemiri et al, 2015; Kloberg et al,
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2014) with the ability to increase and decrease dopaminergic
activity depending on the prevailing dopaminergic tone
(Rung et al, 2008; Tedroff et al, 1998). Instead of partial
agonism, antagonism at both extrasynaptic dopamine D2
auto- and heteroreceptors (Tolboom et al, 2014) has been
hypothesized to underlie this effect. We recently identified
OSU6162 as a potential treatment for alcohol use disorder by
showing that it attenuates alcohol-mediated behaviors
(Steensland et al, 2012) and restores striatal dopaminergic
deficits (Feltmann et al, 2016) in alcohol-drinking rats, as
well as attenuates alcohol craving in alcohol-dependent
humans (Khemiri et al, 2015).
Based on the behavioral and neurochemical similarities
between BED and substance use disorders, together with our
observation that OSU6162 reduced sucrose drinking in rats
(Steensland et al, 2012), we here explored the potential of
OSU6162 as a novel BED treatment using relevant rodent
models. The effect of OSU6162 on food consumption was
investigated using a model of binge-like intake of highly
palatable food (Cottone et al, 2008; Giuliano et al, 2012) and
the ability of OSU6162 to affect the impact of food-associated
cues was investigated using food seeking under a second-
order schedule of reinforcement (Giuliano et al, 2012). In the
latter procedure, animals respond on a fixed-ratio schedule
(FR10) for brief, contingent presentations of reward-
associated conditioned stimuli (CS), acting as conditioned
reinforcers, during two 15 min intervals. Each interval is
terminated by reward delivery (20 chocolate-flavored sucrose
pellets). This procedure was used to investigate whether
OSU6162, compared with dopamine D1 and D2 receptor
antagonists, affects high-incentive food reward seeking
directly (first interval, before reward delivery) or indirectly
via alteration of the hedonic impact of food ingestion
(second interval, after reward delivery) (Giuliano et al, 2012).
Furthermore, to evaluate whether potential effects would be
specific to prolonged seeking and CS responding, the effects
of the compounds were also investigated under fixed interval
(FI) schedules: one involving frequent reward delivery
(1 min, FI1) and one similar to the second-order schedule
but without contingent CS presentations (FI15). Finally, to
identify brain areas involved in mediating the systemic
effects of OSU6162 on the second-order schedule, local
bilateral OSU6162 infusions were given into the NAc core
and dorsolateral striatum (DLS). These two structures were
targeted as they, in contrast to the NAc shell, have been
consistently shown to be implicated in conditioned reinfor-
cement and in the effects of conditioned reinforcers on
instrumental seeking behavior in a second-order schedule of
reinforcement (Ito et al, 2000); for example, the integrity of
the NAc core is necessary for the expression of conditioned
reinforcement and the acquisition of a novel response for a
food- or cocaine-paired conditioned reinforcer (Di Ciano,
2008; Di Ciano and Everitt, 2004; Parkinson et al, 1999).
MATERIALS AND METHODS
Detailed descriptions of animals (male Lister Hooded rats
(Charles River, Margate, UK)), housing conditions, intra-
cranial guide cannula implantation and drug infusion,
histological assessment of cannula placement, and drugs
and chemicals are available in Supplementary Information.
All procedures were conducted according to the UK Animal
(Scientific Procedures) Act 1986 Amendment Regulations
2012, following ethical review by the University of Cam-
bridge Animal Welfare and Ethical Review Body (AWERB).
Binge-Like Eating of Highly Palatable Food
Paradigm. The binge-eating procedure was used to induce
a binge-like hyperphagia of palatable food and a prior chow
hypophagia in anticipation of the palatable food (negative
anticipatory contrast).
The procedure was performed as described previously
(Cottone et al, 2008; Giuliano et al, 2012) but minor
modifications were made. In brief, male rats with free access
to rodent chow in the home cage throughout the experiment
were transferred daily to behavioral chambers. After 2 h of
food deprivation, rats had access to chow in one (first) and
then another (second) feeder for 10 min in each feeder. After
20 sessions rats were divided into two groups, both of which
had access to chow from the first feeder and chocolate-
flavored sucrose pellets (chow/sucrose group, n= 10) or
chow (chow/chow group, n= 10) from the second feeder,
respectively (Figure 1a).
Treatment. To ensure binge-like eating in the chow/
sucrose group, testing began at least 15 sessions after the
chocolate-flavored sucrose pellets had been introduced in the
second feeder (Figure 1a). Thereafter, OSU6162 (5, 10, 15,
and 30 mg/kg, subcutaneously (i.p.)) or vehicle were
administered 60 min before giving access to the first feeder
using a Latin square design with 2 days of re-baselining in
between injections. One rat in the binge-eating paradigm was
excluded from analysis because of ill health.
Seeking of Highly Palatable Food: Second-Order
Schedule of Reinforcement
Paradigm. The second-order schedule of high-incentive
food reinforcement procedure was performed as previously
described (Giuliano et al, 2012), except that rats in the
present experiment were given unlimited access to food in
the home cages throughout the experiment. Briefly, 24 rats
were initially trained in operant chambers to press a lever
under a FR1 schedule for delivery of chocolate-flavored
sucrose pellets, paired with a 20 s light stimulus (CS).
Following five sessions on FR1 (Figure 1b), sessions under FI
schedules were introduced during which pellet delivery and
20 s CS presentation was restricted to the first lever press
after the end of each 1 min interval (FI1). After ∼15 sessions
on FI1, the length of the intervals was progressively increased
up to 15 min (FI15) during six sessions (FI2, FI4, FI6, FI8,
FI10, and FI15), whereas the maximum total number of 40
pellets/session remained constant (ie, during a FI15 session,
20 pellets were delivered together with a 20 s CS at the end of
each of the two intervals). Following 13 sessions on FI15, a
second-order schedule of reinforcement was introduced,
differing only from the FI15 schedule in the presentation of a
brief 1 s CS together with every tenth lever press during each
interval. Pellet consumption was assessed by checking for
any remaining pellets in the food tray at the end of each
session.
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Treatment. The animals were divided into three groups
(matched for baseline FI1 responding, n= 8 per group) and
treated with OSU6162 (5, 10, and 15 mg/kg, s.c.), raclopride
(0.01, 0.03, and 0.1 mg/kg, s.c.), or SCH23390 (0.003, 0.01,
and 0.03 mg/kg, intraperitoneally (i.p.)), respectively. Testing
was conducted within each treatment group after reaching
stable baseline performance on FI1, FI15, and second-order
schedules, respectively, using a Latin square design within
each schedule with at least 2 days of rebaselining in between
injections.
Surgical procedures and intracerebral infusions. Two
cohorts of rats trained on the second-order schedule of
reinforcement (Figure 1c) were implanted bilaterally with
guide cannulae above the NAc core (AP +1.7, ML ± 1.9,
DV –1.5) or DLS (AP +1.2, ML ± 3.0, DV  2.0). The first
cohort was the same as in the previous experiment
(systemic injections of OSU6162, raclopride, or
SCH23390); surgery took place within 2 weeks after the last
injection on the second-order schedule. The second group
was prepared using a similar training procedure with the
exception of shorter FI1 and FI15 schedules as no drug
testing was conducted.
OSU6162 (0.5, 1.5, and 5 μg/0.5 μl/side, Latin square
design) was bilaterally infused into the NAc core or DLS
5 min before the start of the session. Only animals with
cannula placements in the target areas were included
in the statistical analysis (see details in Supplementary
Information).
Statistical Analysis
To identify overall effects on acquisition of the binge-like
eating behavior, food intake (kcal) was analyzed using
repeated-measures analysis of variance (ANOVA) with diet
(group: chow/chow, chow/sucrose) as the between-subject
Binge-eating model
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Figure 1 Timeline of experimental procedures. (a) In the binge-eating paradigm, rats were trained daily in behavioral chambers, including access to food in
feeder 1, followed by access to feeder 2 (10 min per feeder). During the training phase (20 days), all rats got access to chow in both feeders. Thereafter, rats
were divided into a control group, continuing the chow/chow access and one group receiving chow from the first, and chocolate-flavored sucrose pellets from
the second feeder. After 15 days, food intake in each group had stabilized and drug testing was conducted. (b) To train rats in the second-order schedule of
reinforcement, rats were initially trained on a fixed ratio (FR) 1 schedule, followed by fixed interval (FI) schedules of increasing length ranging from 1 min (FI1)
to 15 min (FI15, second-order). During FI1, FI15, and second-order (SO) schedules, drug testing was performed. (c) To test the effects of drugs administered
locally into the brain, rats that had been trained under the second-order schedule (SO) of reinforcement for 35 days were implanted with guide cannulae.
Following 2 weeks of recovery, rats were retrained for 4 days before testing of local infusions started. (a–c) Drug testing was conducted using a Latin square
design, ie, each rat received each dose, with 2 days of rebaselining in between injections. The period of each training and testing stage is indicated.
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factor and day and feeder as within-subject factors.
Significant main effects of diet were followed by repeated-
measures ANOVA with day and feeder as within-subject
factors for each diet group separately. Significant feeder ×
session interactions were followed by repeated-measures
ANOVA within each feeder. A significant main effect of day
was followed by Sidak post hoc to evaluate significant
changes against day 1.
To detect overall effects of OSU6162 treatment in the
binge-like eating model, food intake (kcal) was analyzed
using repeated-measures ANOVA with diet group as the
between-subject factor and feeder and treatment as
within-subject factors. Upon confirmation of a significant
main effect of diet, repeated-measures ANOVA with
treatment and feeder as within-subject factors were
performed for each diet group separately and significant
feeder × treatment interactions were followed by repeated-
measures ANOVA within each feeder. Significant main
effect of treatment was followed by within-subject
contrasts to vehicle.
Effects of systemic and intracerebral drug treatments on
operant food seeking under FI1, FI15, and second-order
schedules were analyzed using separate one-way repeated-
measures ANOVAs for each drug and schedule as well as
within each 15 min interval. Data of the FI15 and second-
order schedule were not normally distributed and therefore
square root transformed before analysis. Note that the non-
transformed number of lever presses is presented in the
figures for the sake of clarity. Significant treatment effects
were followed by within-subject contrasts to vehicle.
Statistical analyses were performed using the software
SPSS (version 22, Chicago, IL) and all values were reported
as mean± SEM. The significance level was set at α⩽ 0.05.
RESULTS
Binge-like Eating Is Induced by Limited Access to
Chocolate-Flavored Sucrose Pellets
A binge-like eating pattern (ie, escalation of sucrose intake
over time) was achieved by giving rats daily exposure to the
following paradigm during 15 days of training: 2 h food
deprivation, 10 min access to chow in the first feeder,
followed by a 10 min access to either chow (chow/chow
group) or chocolate-flavored sucrose pellets (chow/sucrose
group) in the second feeder. There were significant overall
main effects of diet group (ie, chow/chow vs chow/sucrose;
F1, 17= 118.3, po0.001), session (F14, 238= 18.6, po0.001),
and feeder (F1, 17= 100.6, po0.001), as well as a diet ×
session × feeder interaction (F14, 238= 17.9, po0.001).
Within-group analyses revealed significant session × feeder
interactions in both diet groups (chow/chow: F14, 112= 2.9,
po0.01; chow/sucrose: F14, 126= 42.5, po0.001). In the
chow/chow group (Figure 2a) there was a stable chow intake
Figure 2 OSU6162 reduces intake of highly palatable food in a binge-like eating paradigm. The binge-eating procedure used consisted of three contiguous
phases: 2 h food deprivation, first feeder: 10 min access to chow (closed circles), second feeder: 10 min access to chow (open circles) or chocolate-flavored
sucrose pellets (open squares). Values represent the mean± SEM food intakes in kcal (n= 9–10/group). The chow/chow-fed rats (a) displayed stable intake of
chow over 15 sessions. The chow/sucrose-fed rats (b) escalated in sucrose intake while reducing prior chow intake (‘anticipatory negative contrast’). Following
the 15 sessions (in a, b), OSU6162 (0, 5, 10, 15, and 30 mg/kg) was tested for effects on food intake in the chow/chow (c) and the chow/sucrose (d) group.
Within each group, each rat received each dose and thus served as its own control. In the chow/chow-fed rats (c), OSU6162 (10 and 30 mg/kg) significantly
reduced chow intake compared with vehicle upon analysis of both feeders together due to lack of a significant session × feeder interaction (repeated-measures
ANOVA and within-subject contrast to vehicle). In the chow/sucrose-fed rats (d), significant effects of treatment compared with vehicle are displayed
(*po0.05, **po0.01, repeated-measures ANOVA and within-subject contrast to vehicle).
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in both feeders during the 15 sessions. The post hoc analysis
revealed that the chow/sucrose group significantly increased
the sucrose consumption to binge-like levels on each session
compared with the first session (Figure 2b) and significantly
decreased the chow intake starting from session 6, ie, they
displayed an anticipatory negative contrast effect, under-
eating the first presented food in expectation of access
to the more highly preferred chocolate-flavored sucrose
pellets (Giuliano et al, 2012). Sucrose intake was similar
to the binge-like levels previously reported in female
Lister Hooded (Giuliano et al, 2012) and Wistar rats
(Cottone et al, 2008).
OSU6162 Reduced Binge-Like Eating of Chocolate-
Flavored Sucrose Pellets
OSU6162 significantly reduced binge-like intake of
chocolate-flavored sucrose pellets, but did not significantly
affect the negative anticipatory contrast.
The effect of OSU6162 (5, 10, 15, and 30 mg/kg, s.c.)
on binge-like eating was evaluated after 15 sessions in the
Figure 3 Effects of OSU6162, raclopride, and SCH23390 on seeking for highly palatable food under a fixed interval (FI) 1 and 15 min and a second-order
schedule of reinforcement. Effects of OSU6162 (0, 5, 10, and 15 mg/kg, a–c), raclopride (0, 0.01, 0.03, 0.1 mg/kg, d–f), and SCH23390 (0, 0.003, 0.01, and
0.03 mg/kg, g–i) (n= 8/group) on seeking for highly palatable food under a second-order (left panel) schedule and fixed interval schedules of 15 min (FI15,
central panel) and 1 min (FI1, right panel) of reinforcement are displayed. In both the second-order and FI15 schedule, 20 pellets (chocolate-flavored sucrose)
together with a 20 s conditioned stimuli (CS) were delivered at the end of each 15 min interval, leading to the first interval (before reward delivery) and
second interval (after reward delivery). The second-order schedule differed from FI15 by presentation of a contingent 1 s CS upon every tenth active lever
presses during an interval. In the FI1 schedule, 1 pellet and a 20 s CS were delivered upon an active lever press first after 1 min had elapsed, leading to 40
pellets delivered in total. Values represent mean± SEM number of active lever presses during each interval. Within each treatment group, each rat received
each dose and thus served as its own control. Significant effects of treatment on active lever presses compared with vehicle are displayed (*po0.05,
**po0.01, ***po0.001, repeated-measures ANOVA and within-subject contrast to vehicle).
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binge-eating paradigm. OSU6162 treatment significantly
affected food intake, as indicated by a significant main
effect of treatment (F4, 48= 16.2, po0.001), and also affected
food intake differently in each diet group, depending on
the feeder, as indicated by significant main effects of diet
group (F1, 17= 227.8, po0.001), feeder (F1, 17= 144.5,
po0.001), and a diet group × treatment × feeder interaction
(F3.3, 56.8= 16.5, po0.001). In the chow/chow group
(Figure 2c), there was a significant main effect of treatment
(F4, 32= 7.7, po0.001) but no feeder × treatment interaction
(F4, 32= 0.9, NS). Hence, analyzing both feeders together,
within-subject contrast to vehicle revealed that OSU6162 at
10 (po0.05) and 30 mg/kg (po0.001) significantly
reduced chow intake. In the chow/sucrose group
(Figure 2d), there was a significant main effect of treatment
(F4, 36= 9.7, po0.001) and a significant feeder × treatment
interaction (F2.1, 19.1= 22.9, po0.001). Within-subject
contrasts to vehicle for each feeder revealed that 15 and
30 mg/kg OSU6162 significantly reduced sucrose, but did
not significantly affect chow intake. Hence, there was no
significant effect of OSU6162 on the anticipatory negative
contrast.
OSU6162 Reduced Cue-Controlled Seeking for
Chocolate-Flavored Sucrose Pellets
The effects of OSU6162 (5, 10, and 15 mg/kg, s.c.), raclopride
(0.01, 0.03, and 0.1 mg/kg, s.c.), and SCH23390 (0.003, 0.01,
and 0.03 mg/kg, i.p.) were evaluated on seeking behavior
motivated by chocolate-flavored sucrose pellets under the
second-order schedule of reinforcement and during prior
training stages (FI1 and FI15).
OSU6162 treatment significantly affected seeking behavior
under the second-order schedule (Figure 3a) during the first
interval (before sucrose ingestion) (F3, 21= 4.1, po0.05), but
not during the second interval (after sucrose ingestion)
(F3, 21= 1.1, NS). Within-subject contrasts to vehicle revealed
that OSU6162 (15 mg/kg) significantly reduced the respond-
ing on the active lever during the first interval only, before
delivery of food. Under the FI15 schedule (Figure 3b),
OSU6162 treatment produced an overall main effect during
the first (F3, 21= 3.3, po0.05) but not the second interval
(F3, 21= 1.5, NS). However, within-subject contrast to vehicle
revealed no significant effects of any dose. Seeking under FI1
was not affected by OSU6162 (Figure 3c, F3, 21= 2.0, NS).
The D2-receptor antagonist raclopride significantly re-
duced sucrose-seeking behavior under the second-order
2.20 mm
1.70 mm
1.60 mm
1.20 mm
Figure 4 Histological illustration of locations of infusions into nucleus accumbens core and dorsolateral striatum. Guide cannulas were implanted above the
nucleus accumbens (NAc, n= 15) core or dorsolateral striatum (DLS, n= 14). Coronal sections from +2.2 to +1.2 mm anteroposterior from bregma
represent histological verified locations of infusions into NAc core (filled circles) and DLS (filled squares) (a). Representative photomicrographs of Cresyl
violet-stained coronal sections of NAc core- (b) and DLS- (c) cannulated rat brains, showing the guide cannula damage above and the infusion track into the
targeted areas.
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(Figure 3d, first interval: F1.4, 10.5= 15.5, po0.01; second
interval: F3, 21= 4.8, po0.05), the FI15 (Figure 3e, first
interval: F3, 21= 12.9, po0.001; second interval: F3, 21= 8.4,
po0.01), and the FI1 (Figure 3f, F3, 21= 5.1, po0.01)
schedules. Within-subject contrasts to vehicle revealed that
raclopride at the highest dose (0.1 mg/kg) significantly
reduced lever pressing during all schedules and both
intervals. Raclopride 0.01 mg/kg significantly reduced re-
sponding in the first interval of the second-order schedule
compared with vehicle and at a dose of 0.03 mg/kg
significantly reduced lever pressing during the second
interval of the FI15 schedule.
SCH23390 treatment did not affect seeking behavior under
either the second-order (Figure 3g, first interval: F3, 21= 1.0,
NS; second interval: F3, 21= 0.9, NS), the FI15 (Figure 3h,
first interval: F3, 21= 0.2, NS; second interval: F3,21= 1.7, NS),
or the FI1 (Figure 3i, F3, 21= 0.7, NS) schedule.
None of the evaluated compounds affected pellet con-
sumption in any schedule compared with vehicle; all rats
consumed all pellets at the end of each interval during
testing.
Effects of Local Infusion of OSU6162 into the NAc Core
or DLS on Cue-Controlled Seeking of Chocolate-
Flavored Sucrose Pellets
To evaluate the involvement of the NAc core and DLS in the
effects of OSU6162 on cue-controlled sucrose seeking under
a second-order schedule of reinforcement, OSU6162 (0.5,
1.5, and 5 μg/side) was bilaterally infused in either brain area
before testing (Figure 4). OSU6162 infused into the NAc core
(Figure 5a, n= 15) reduced responding for sucrose in the first
(before sucrose ingestion) (F3, 42= 9.2, po0.001) but not in
the second interval (after sucrose ingestion) (F3, 42= 1.4, NS).
Within-subject contrasts to vehicle revealed that animals
treated with OSU6162 at 1.5 and 5 μg/side significantly
reduced active lever pressing in the first interval. In contrast,
OSU6162 infused into the DLS (Figure 5b, n= 14), had no
effect on responding for food in either the first (F3, 39= 1.4,
NS) or the second interval (F3, 39= 0.07, NS).
DISCUSSION
The monoamine stabilizer OSU6162 reduced binge-like
consumption of chocolate-flavored sucrose pellets. More-
over, systemic as well as local administration of OSU6162
into the NAc core, but not the DLS, reduced cue-controlled
seeking behavior for these pellets under a second-order
schedule of reinforcement. Thus, OSU6162 affects both
consummatory and appetitive behaviors of relevance to BED.
OSU6162 reduced sucrose intake in rats that had been
trained to consume binge-like quantities of chocolate-
flavored sucrose pellets during brief daily access in
behavioral chambers. However, OSU6162 did not signifi-
cantly alter chow intake from the first feeder (before sucrose
access). These results suggest that the monoamine-stabilizing
effects of OSU6162 suppress overeating of palatable food in a
model of BED directly during consumption without affecting
prior anticipation. Furthermore, we previously reported that
another potential treatment for BED, the selective μ-opioid
receptor antagonist GSK1521498, decreased bingeing on
chocolate-flavored sucrose pellets and increased prior chow
intake, suggestive of a decreased anticipatory negative
contrast (Giuliano et al, 2012). Hence, we suggested that
GSK1521498 has a specific effect on the impact of the
hedonic value of the palatable food (Giuliano et al, 2012),
whereas we found no evidence for an effect on anticipatory
negative contrast after OSU6162 treatment in the current
study. Together, these findings could indicate that opioid
mechanisms are more important than dopamine signaling in
anticipatory negative contrast or that any dopaminergic
influence on this phenomenon is not blocked by OSU6162.
OSU6162 reduced chow intake in the chow/chow group
(control group for the sucrose bingeing rats) in contrast to
our previous study where GSK1521498 did not produce this
effect (Giuliano et al, 2012). This indicates that OSU6162 is
not generally specific to palatable food and can reduce intake
of bland food. This apparent discrepancy to the effects in the
sucrose-bingeing rats might be because of the fact that rats in
the chow/chow group consumed higher amounts of chow
from the first feeder than rats in the chow/sucrose group.
Figure 5 The role of the ventral and dorsal striatum in the effects of OSU6162 on seeking for highly palatable food under a second-order schedule of
reinforcement. Effects of OSU6162 (0, 0.5, 1.5, and 5 μg/side) infused into either the (a) nucleus accumbens (NAc) core (n= 15) or (b) dorsolateral striatum
(DLS, n= 14) on seeking for highly palatable food under a second-order schedule of reinforcement are displayed. At the end of each 15 min interval, 20 pellets
(chocolate-flavored sucrose) together with a 20 s conditioned stimuli (CS) were delivered, leading to the first interval (before reward delivery) and second
interval (after reward delivery). During each interval, contingent 1 s CS were presented upon every tenth active lever press. Values represent mean± SEM
number of active lever presses during each interval. Within each treatment group, each rat received each dose and thus served as its own control. Significant
effects of treatment on active lever presses compared with vehicle are displayed (*po0.05, **po0.01, repeated-measures ANOVA and within-subject
contrast to vehicle).
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These results, together with the attenuation of sucrose binge-
like eating, suggest that OSU6162 moderates intake only if
the amounts of food consumed are relatively high, regardless
of palatability. This suggestion is further supported by the
finding that OSU6162 attenuated binge-like eating
(34± 2 kcal sucrose) but did not affect sucrose consumption
in the seeking procedures (40 pellets = 0.15 kcal). A similar
selective, decreasing effect of OSU6162 only when the
baseline is high, has previously been reported for locomotor
activity (Natesan et al, 2006; Rung et al, 2008), alcohol intake
(Steensland et al, 2012) and striatal L-[11C]DOPA influx rate
(Tedroff et al, 1998).
The mechanisms behind the monoamine-stabilizing effects
of OSU6162 are not fully understood, but there are several
plausible explanations for its effects on food intake in the
present study. First, intake of palatable food, including
sucrose, induces a peak in dopamine levels in the NAc,
potentially coding for the motivational value of the food
(Bassareo et al, 2002; Rada et al, 2005; Wilson et al, 1995).
Thus, based on our previous finding showing that OSU6162
diminishes alcohol-induced NAc dopamine output in
alcohol-naive rats (Steensland et al, 2012), we speculate
that OSU6162 might attenuate this sucrose-induced dopa-
mine peak, reducing the motivation to consume sucrose.
Second, it is possible that an OSU6162-induced increase in
dopaminergic tone before food presentation might underlie
the reduction in food intake. This hypothesis is supported
by rodent studies showing that: (1) OSU6162 slowly
increases and maintains a stable elevated NAc dopamine
output for several hours (Feltmann et al, 2016; Steensland
et al, 2012); (2) optogenetically induced stable NAc
dopamine release reduces voluntary sucrose intake
(Mikhailova et al, 2016); (3) the dopamine-releasing
compound lisdexamfetamine attenuates binge-like eating of
chocolate (Vickers et al, 2015); and (4) the dopamine-
releasing compound methylphenidate reduces food con-
sumption in humans and rodents (Davis et al, 2012; Thanos
et al, 2015). Nevertheless, further studies are needed to
elucidate the mechanism underlying the effect of OSU6162
to reduce food consumption.
In the cue-controlled sucrose-seeking (second-order sche-
dule of reinforcement) procedure, OSU6162 significantly
reduced responding during the first interval (before
sucrose consumption), but not the second interval (after
sucrose consumption). These results indicate that OSU6162
reduced incentive responding for the reward without
affecting its hedonic value, consistent with the theory that
the dopamine system is primarily involved in incentive
motivation, but not hedonic aspects of food reward (Barbano
and Cador, 2007; Berridge, 2007; Kelley et al, 2002).
This effect is again in contrast to our previous findings with
GSK1521498, which reduced seeking during both intervals
(Giuliano et al, 2012), suggesting that μ-receptor antagonism
attenuates both the incentive motivational and hedonic
impact of palatable food reward (for a review, see (Giuliano
and Cottone, 2015).
The traditional dopamine D2 receptor antagonist raclo-
pride, in contrast to OSU6162, reduced sucrose seeking
under all schedules (FI1, FI15, and second-order), indicating
that raclopride has a more general effect on seeking than
OSU6162. These results indicate that although D2 dopamine
receptors seem to be implicated in the effects of OSU6162 on
cue-controlled sucrose seeking, the mechanism of action
might differ between OSU6162 and raclopride. Accordingly,
and in contrast to traditional D2 receptor antagonists,
OSU6162 does not induce catalepsy at high (80%) striatal
D2/D3 occupancies in rodents (Natesan et al, 2006;
Rung et al, 2008) or primates (Ekesbo et al, 1999). Moreover,
the recent finding that OSU6162 occupies a maximum
of 40% of striatal D2/D3 receptors in humans led to the
hypothesis that OSU6162 might preferentially antagonize
extrasynaptic, relative to synaptic, D2 receptors (Tolboom
et al, 2014), potentially explaining the lack of extrapyramidal
side effects (Johansson et al, 2012; Khemiri et al, 2015;
Kloberg et al, 2014).
Intracranial infusion of OSU6162 into the NAc core
recapitulated the systemic effects of the compound, resulting
in decreased sucrose seeking under the second-order
schedule of reinforcement during the first (pre-reward),
but not second, interval. The NAc core is an important site
mediating the capacity of food-associated conditioned
reinforcers to control seeking behavior (Parkinson et al,
1999). Specifically, dopamine receptors within the NAc
mediate sucrose seeking (Ikemoto and Panksepp, 1996), cue-
induced reinstatement of food seeking (Floresco et al, 2008),
and CS-dependent Pavlovian-Instrumental Transfer (Lex
and Hauber, 2008). Whereas both systemic and local
treatment with OSU6162 reduced seeking under the
second-order schedule of reinforcement, none of the
OSU6162 doses tested significantly reduced seeking under
the FI15 schedule compared with vehicle, suggesting that
OSU6162 interacts specifically with the conditioned reinfor-
cing effects of food-associated cues. This might be particu-
larly important in BED, where environmental cues such as
commercials or smells often induce food cravings that are
alleviated by seeking and ingestion of the food (Curtis and
Davis, 2014; Sobik et al, 2005).
Infusions of OSU6162 into the DLS did not affect
responding under the second-order schedule of reinforce-
ment for sucrose, indicating that OSU6162 does not
influence the stimulus-response mechanism located in this
striatal domain. These results appear to be in contrast to
previous studies showing that the mixed D1/D2 receptor
antagonist α-flupenthixol infused into the DLS reduced
habitual cocaine seeking under this schedule (Belin and
Everitt, 2008; Murray et al, 2012). This discrepancy might
reflect a primary involvement of D1 signaling in the DLS,
although this suggestion is contradicted by the present lack
of effects of systemic SCH23390 administration. Alterna-
tively, if there is a primary involvement of D2 signaling, this
discrepancy could also reflect the suggested differences in the
mechanisms of action of OSU6162 compared with tradi-
tional D2 receptor antagonists. Nevertheless, the involve-
ment of the DLS and the effects of dopaminergic
manipulations in the DLS on food seeking under the
second-order schedule require further investigation.
In conclusion, the present study demonstrates that the
monoamine stabilizer OSU6162 has the ability to reduce
both binge-like eating and cue-controlled food seeking in
rats. Together with a favorable side-effect profile in humans
(Johansson et al, 2012; Khemiri et al, 2015; Kloberg et al,
2014), these results warrant further investigation of the
potential of the monoamine stabilizer OSU6162 as a novel
treatment for BED.
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